The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong vote of confidence in Regulus Therapeutics. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term, especially if the market perceives this as a signal of underlying value and future growth prospects.